modelN06BX03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Piracetam | |
| ATC code: | N06BX03 | route: | oral |
| compartments: | 1 | |
| dosage: | 1200 | mg |
| volume of distribution: | 42 | L |
| clearance: | 6.02 | L/h |
| other parameters in model implementation | ||
Piracetam is a nootropic agent, classified as a cyclic derivative of GABA, used to treat cognitive impairment and myoclonus. It is not FDA approved in the United States but is approved in some European and other countries for cognitive disorders, vertigo, and myoclonus.
Pharmacokinetics
Pharmacokinetics reported in healthy adult volunteers of both sexes after oral administration.
References
Rhee, SJ, et al., & Lee, SK (2017). Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy research 132 8–14. DOI:10.1016/j.eplepsyres.2017.02.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28279893
Hernández-Mitre, MP, et al., & Milán-Segovia, RDC (2020). Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. Journal of pharmaceutical sciences 109(6) 2070–2078. DOI:10.1016/j.xphs.2020.02.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32113977
Pigeolet, E, et al., & Stockis, A (2007). Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clinical pharmacokinetics 46(6) 503–512. DOI:10.2165/00003088-200746060-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17518509
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)